Michael Mueller brings more than 17 years of industry experience in various areas of clinical research within both CROs and sponsors companies. His experience spans a variety of Phase 1 to 4 clinical trials and indications with extensive involvement in oncology, specifically immunotherapy studies. His therapeutic areas of expertise include breast cancer, first-line DLBCL, multiple myeloma, melanoma, muscle invasive bladder cancer, non-small cell lung cancer, and acute myeloid leukemia.
With his experience in global project management from study planning and start-up through close-out and regulatory license applications, Mr. Mueller has developed an acute ability to analyze study processes and devise integration and collaboration strategies.
Current role